Tango (TNGX) Q2 Revenue Drops 52%

Tango Therapeutics (TNGX 4.55%), a biotechnology firm advancing targeted oncology therapies, posted its second quarter results on August 5, 2025. The highlight of the release was a steep decline in GAAP revenue, well below consensus, along with a larger net loss compared to analyst expectations. Revenue (GAAP) came in at $3.2 million—less than half of the $6.7 million estimate and a 59% drop compared to the same period in 2024. GAAP loss per share widened to ($0.35), compared to an expected ($0.34). The qua ...